Abstract
Tumor cell dissemination is a common phenomenon observed in most cancers of epithelial origin. One-third of breast cancer patients present with disseminated tumor cells (DTCs) in bone marrow at time of diagnosis; these patients, as well as patients with persistent DTCs, have significantly worse clinical outcome than DTC-negative patients. Since DTC phenotype may differ from the primary tumor with regard to ER and HER2 status, reevaluation of predictive markers on DTCs may optimize treatment choices. In the present review, we report on the clinical relevance of DTC detection in breast cancer.
Original language | English |
---|---|
Journal | Cancers |
Volume | 6 |
Issue number | 1 |
Pages (from-to) | 143-152 |
Number of pages | 10 |
ISSN | 2072-6694 |
DOIs | |
Publication status | Published - 03.2014 |